Öztürk Bilgin
Department of Neurology, Gülhane Training and Research Hospital, Ankara, Turkey.
Arch Rheumatol. 2019 Apr 22;34(4):443-446. doi: 10.5606/ArchRheumatol.2019.7249. eCollection 2019 Dec.
Multiple sclerosis (MS) is the most common demyelinating disease in Turkey while familial Mediterranean fever (FMF) is the most common periodic fever syndrome worldwide. In this article, we report a 37-year-old male patient admitted with complaint of difficulty in walking. He had been taking colchicine at admission for 27 years. Despite this therapy, he had been experiencing twice monthly severe FMF attacks. After systemic and neurological examinations, laboratory tests and cranial and spinal magnetic resonance imaging, he was diagnosed as MS. Interferon (IFN) beta-1a was initiated three times/weekly subcutaneously for MS treatment. He stopped colchicine treatment after five months of IFN treatment because he did not suffer from any FMF attacks. He is still attack free for both diseases for a follow-up duration of 12 months. IFN beta is one of the most preferred agents for MS treatment but not one of the agents used for the treatment of FMF. Interferon beta can be a treatment of choice in patients with coincident FMF and MS and can be used in colchicine-resistant patients after being studied in systematic clinical studies.
多发性硬化症（MS）是土耳其最常见的脱髓鞘疾病，而家族性地中海热（FMF）是全球最常见的周期性发热综合征。在本文中，我们报告了一名37岁男性患者，因行走困难入院。他入院时已服用秋水仙碱27年。尽管接受了这种治疗，他仍每月经历两次严重的FMF发作。经过全身和神经系统检查、实验室检查以及头颅和脊髓磁共振成像，他被诊断为MS。开始皮下注射干扰素（IFN）β-1a，每周三次用于MS治疗。IFN治疗五个月后，他停止了秋水仙碱治疗，因为他没有遭受任何FMF发作。在12个月的随访期间，他两种疾病均未发作。IFNβ是MS治疗最常用的药物之一，但不是用于治疗FMF的药物之一。IFNβ可以作为FMF和MS合并患者的治疗选择，并且在经过系统的临床研究后可用于秋水仙碱耐药的患者。
